Results 301 to 310 of about 1,776,183 (353)

ZNF529 up-regulation speeds up progression and induces tyrosine kinase inhibitor resistance in hepatocellular carcinoma. [PDF]

J Gastrointest Oncol
Qin K, Zhou SS, Li JD, Qin DY, Zeng DT, Huang WY, Huang ZG, Yao GP, Chen YZ, Yin BT, Li FX, Wang L, Chen G, He RQ.   +13 more
europepmc   +1 more source

Overcoming EGFR‐Mediated Dendritic Cell Dysfunction to Enhance Anti‐tumor Immunity in EGFR‐Mutant NSCLC by Precisely Targeting CD73 With pH‐responsive Nanocarriers

Advanced Science, EarlyView.
EGFR mutations drive ERK/c‐Jun–mediated transcriptional activation of CD73, elevating adenosine levels and fostering an immunosuppressive TME by impairing DC maturation and CD8⁺ T cell priming. The pH‐responsive nanodrug F127ZIF‐8AB680 selectively inhibits CD73, normalizes adenosine metabolism, and re‐establishes effective anti‐tumor immunity ...
Xiaoling Shang, Xudong Geng, Zixu Wang, Shumin Yuan, Shanshan Ding, Ni Liu, Xinchun Ma, Xuan Sun, Huimin Wang, Ying Sun, Xun Qu, Guangwen Ren, Yong Qiang Li, Xiuwen Wang, Yanguo Liu   +14 more
wiley   +1 more source

Considerations for the practical management of cardiovascular risk with Bruton's tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia. [PDF]

Oncologist
Lenihan D, Bloom M, Copeland-Halperin R, Fleming MR, Fradley M, O'Quinn R, Bhat SA.   +6 more
europepmc   +1 more source

TSH Ligand‐Based CAR‐T Cell Effectively Eradicates TSHR‐Positive Thyroid Cancer with Favorable Safety Profile

Advanced Science, EarlyView.
TSHR is highly expressed in differentiated thyroid cancer (DTC), making it an ideal target for adoptive immune cell therapy. A novel Ligand‐based TSH‐CAR‐T cell approach effectively eradicated TSHR‐positive thyroid tumors in vitro and accomplished full remission in tumor models with favorable safety profile, highlighting that TSH‐CAR‐T cells could ...
Fei Wang, Hui Zuo, Li Liu, Shiyuan Wang, Haifang Zhao, Zhao Liu, Gang Wang, Zhao Liu, Junnian Zheng, Chuan Xu, Hongwei Du   +10 more
wiley   +1 more source

Bibliometric analysis of hepatocellular carcinoma and tyrosine kinase inhibitors. [PDF]

Medicine (Baltimore)
Wu W, Mao H, Song J, Yang F.
europepmc   +1 more source

Syntaxin 3B Mediates Light‐Dependent Interactions with STXBP1 and Arrestin 4: Distinct Roles in Rods and Cones

Advanced Science, EarlyView.
The present study investigates a cone‐specific STX3 knockout model, displaying a complete loss of cone function, a later onset reduction in rod function, and photoreceptor cell death. A cone‐specific depletion of STXBP1 and ARR4 could be observed in this model.
Lars Tebbe, Larissa Ikelle, Mustafa S. Makia, Mashal Kakakhel, Muayyad R. Al‐Ubaidi, Muna I. Naash   +5 more
wiley   +1 more source

Inhibition of tyrosine kinase BMX increases cell death in response to existing chemotherapeutic agents overcoming apoptotic resistance in cancer. [PDF]

Cell Death Dis
Morad D, Skinner S, Bowman K, Seewooruthun C, Fox JL.   +4 more
europepmc   +1 more source

Functional, Pharmacogenomic, and Immune Landscapes of Long Non‐Coding RNAs in Cancer

Advanced Science, EarlyView.
A systematic analysis of 33 cancer types reveals widespread associations between lncRNAs and cancer pathways, drug responses, immune features, and immunotherapy outcomes. The study identifies key lncRNAs linked to therapeutic response and adverse events and introduces PILNC, an interactive web portal for exploring the functional, pharmacogenomic, and ...
Runhao Wang, Mei Luo, Yuan Liu, Jingwen Yang, Yamei Chen, Chengxuan Chen, Lifei Ma, Stephanie Ding, James Wengler, Yong Zang, Bora Lim, Wenbo Li, Liuqing Yang, Chunru Lin, Lixia Diao, Leng Han   +15 more
wiley   +1 more source

Disparate patterns of disease time burden in patients with HCC on immunotherapy or tyrosine kinase inhibitors. [PDF]

JHEP Rep
Hui RW, Chung MS, Li L, Mao X, Chiang CL, Wong CK, Wong IC, Cheung KS, Yuen MF, Seto WK, Mak LY.   +10 more
europepmc   +1 more source